| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1803-MM, Maintenance, Len vs Len/Dara | 1 | N | 0 Screening | 1420 | 1448 | 206 | 66 | 0 | 0 | 0 | 08/13/2019 | 334 | 127 |
| 1448 | 206 | 66 | 0 | 0 | 0 | |||||||||
| 2 | Y | 1 Lenalidomide | 674 | 102 | 38 | 9 | 1 | 1 | 08/13/2019 | |||||
| 2 Lenalidomide + Daratumumab | 662 | 98 | 36 | 7 | 0 | 0 | ||||||||
| 1336 | 200 | 74 | 16 | 1 | 1 | |||||||||
| 3 | Y | 3 Stop vs Continue Treatment | 269 | 86 | 50 | 36 | 7 | 2 | 08/13/2019 | |||||
| 269 | 86 | 50 | 36 | 7 | 2 | |||||||||
| S2005-WM, Prev. Untreated, I/R +/- Venetoclax | 1 | Y | 1 I+R | 92 | 8 | 7 | 4 | 2 | 2 | 1 | 01/05/2022 | 89 | 23 | |
| 2 I+R+Venetoclax | 1 | 0 | 0 | 0 | 0 | 0 | ||||||||
| 3 V+R | 6 | 6 | 2 | 1 | 1 | 0 | ||||||||
| 15 | 13 | 6 | 3 | 3 | 1 | |||||||||
| S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D | 1 | Y | 1 VRD-R | 510 | 28 | 20 | 12 | 7 | 1 | 0 | 10/12/2023 | 269 | 89 | |
| 2 DRD-R | 26 | 18 | 10 | 4 | 1 | 0 | ||||||||
| 3 DRD-DR | 25 | 18 | 8 | 5 | 1 | 0 | ||||||||
| 79 | 56 | 30 | 16 | 3 | 0 | |||||||||
| S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT | 1 | Y | 0 Induction | 338 | 12 | 12 | 7 | 3 | 1 | 1 | 07/01/2024 | 153 | 45 | |
| 12 | 12 | 7 | 3 | 1 | 1 | |||||||||
| 2 | Y | 1 Dara-VCD | 3 | 3 | 2 | 2 | 1 | 0 | 07/01/2024 | |||||
| 2 Melphalan + ASCT | 3 | 3 | 3 | 1 | 1 | 0 | ||||||||
| 6 | 6 | 5 | 3 | 2 | 0 | |||||||||
| 3 | Y | 3 Dara | 1 | 1 | 1 | 1 | 0 | 0 | 07/01/2024 | |||||
| 1 | 1 | 1 | 1 | 0 | 0 | |||||||||
| Yes | EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) | 0 | E | Total Registrations | 54 | 8 | 4 | 3 | 1 | 0 | 05/27/2021 | 229 | 78 | |
| 54 | 8 | 4 | 3 | 1 | 0 | |||||||||
| 1 | E | Total Registrations | 40 | 5 | 3 | 3 | 1 | 0 | 05/27/2021 | |||||
| 40 | 5 | 3 | 3 | 1 | 0 | |||||||||
| 2 | E | Total Registrations | 29 | 12 | 3 | 0 | 0 | 0 | 05/27/2021 | |||||
| 29 | 12 | 3 | 0 | 0 | 0 | |||||||||
| No | EAA173-MYEL, SMM, Rd +/- Daratumumab | 0 | E | Total Registrations | 76 | 9 | 2 | 1 | 1 | 1 | 01/08/2020 | 252 | 100 | |
| 76 | 9 | 2 | 1 | 1 | 1 | |||||||||
| 1 | E | Total Registrations | 37 | 8 | 2 | 0 | 0 | 0 | 01/08/2020 | |||||
| 37 | 8 | 2 | 0 | 0 | 0 | |||||||||
| Study | Registration/Phase | Open Date | # of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|
| S2005 WM, Prev. Untreated, I/R +/- Venetoclax | 2 Crossover | 24-Jun-21 | 89 | 23 |